CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients with Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase

Melissa Johnson, Jordi Rodon Ahnert, Nehal Lakhani, Rachel E. Sanborn, Anthony El-Khoueiry, Navid Hafez, Hirva Mamdani, Valentina Boni, Henry Castro, Alison L. Hannah, Alexander Spira. Presented at the IASLC 2020 World Conference on Lung Cancer Singapore virtual meeting, January 28-31, 2021.